Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ibrutinib works in treating patients with hairy cell
leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth.